Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Gomez-Larrauri (Barakaldo-Bizkaia, Spain), B. Ortiz De Urbina (Barakaldo-Bizkaia, Spain), J. Andia (Barakaldo-Bizkaia, Spain), E. Garay (Barakaldo-Bizkaia, Spain), A. Rezola (Barakaldo-Bizkaia, Spain), S. Pedrero (Barakaldo-Bizkaia, Spain), P. Sobradillo (Barakaldo-Bizkaia, Spain), E. Lopez De Santamaría (Barakaldo-Bizkaia, Spain), L. Martínez (Barakaldo-Bizkaia, Spain), M. Iriberri (Barakaldo-Bizkaia, Spain), N. Marina (Barakaldo-Bizkaia, Spain). Differences in the response to treatment with monoclonal antibodies according to age. 2211

Member's Comments

No comment yet.

Related content which might interest you: Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all? Source: Virtual Congress 2020 – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease Year: 2020 Change of T2-markers in patients with severe uncontrolled asthma treated by monoclonal antibodies: 1 yr follow up Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 Safety profile and clinical activity of multiple subcutaneous (SC) doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in subjects with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010 Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Specific monoclonal antibody to detect the C-terminal peptide of alpha1-antitrypsin: clinical importance Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019 Age is a predictor of efficacy of monoclonal antibodies in allergic severe asthma Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses Year: 2019 Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Reversing the suppression of T-cells: the role of monoclonal antibodies Source: International Congress 2015 – Stop immune tolerance in lung cancer! Year: 2015 Correlates of the SARS-CoV-2 Ag or Total Ig antibody levels with hematological parameters in Greek hospitalized COVID-19 patients. Source: Virtual Congress 2021 – COVID - 19 around the globe Year: 2021 Long-term treatment with monoclonal antibodies anti-IgE in severe asthma: Follow-up of ten patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Patient characteristics that can predict response to omalizumab an (anti-IgE antibody) for achieving better control of asthmatic patients Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Antigen exposure and IgG antibody response in pigeon fanciers Source: Eur Respir J 2005; 26: Suppl. 49, 374s Year: 2005 The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma Source: Eur Respir J 2001; 18: 45-52 Year: 2001 Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma Source: ERJ Open Res, 7 (3) 00190-2021; 10.1183/23120541.00190-2021 Year: 2021 Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019 Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011 Serum level of specific IgG antibody for aspergillus and its association with severity of asthma in asthmatic children Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases Year: 2012 Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001